New hope for Tough-to-Treat cancers: first human trial of experimental drug begins
NCT ID NCT05652686
Summary
This early-stage study is testing a new drug called PT217 for people with advanced neuroendocrine cancers that have spread or come back after standard treatments. Researchers will first find the safest dose of PT217 given alone, then test it combined with chemotherapy. The goal is to see if the drug can help control these difficult cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
RECRUITINGDuarte, California, 91010, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Mays Cancer Center / University of Texas, San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
-
Sarah Cannon Research Institute University of Oklahoma
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Sidney Kimmel Comprehensive Cancer Center at John Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
-
The University of Texas, MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Washington University School of Medicine (Siteman Cancer Center)
RECRUITINGSt Louis, Missouri, 63108, United States
Conditions
Explore the condition pages connected to this study.